

Boris Gershman

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/91762/publications.pdf>

Version: 2024-02-01

75
papers

1,521
citations

304743

22
h-index

345221

36
g-index

76
all docs

76
docs citations

76
times ranked

2131
citing authors

#	ARTICLE	IF	CITATIONS
1	Real-time diagnosis and Gleason grading of prostate core needle biopsies using nonlinear microscopy. <i>Modern Pathology</i> , 2022, 35, 539-548.	5.5	5
2	Radical cystectomy versus trimodality therapy for muscle-invasive urothelial carcinoma of the bladder. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2022, 40, 272.e1-272.e9.	1.6	16
3	Adjuvant chemotherapy versus observation following radical cystectomy for locally advanced urothelial carcinoma of the bladder. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2022, , .	1.6	2
4	Single black men have the worst prognosis with localized prostate cancer.. <i>Canadian Journal of Urology</i> , 2022, 29, 10992-11002.	0.0	0
5	Do radiation oncologists and urologists endorse decision aids for active surveillance of low-risk prostate cancer: Results from a national survey. <i>European Journal of Cancer Care</i> , 2021, 30, e13301.	1.5	0
6	Contemporary Trends in Magnetic Resonance Imaging at the Time of Prostate Biopsy: Results from a Large Private Insurance Database. <i>European Urology Focus</i> , 2021, 7, 86-94.	3.1	28
7	Development of a Deep Learning Algorithm for the Histopathologic Diagnosis and Gleason Grading of Prostate Cancer Biopsies: A Pilot Study. <i>European Urology Focus</i> , 2021, 7, 347-351.	3.1	44
8	Management of Clinically Regional Node-Positive Urothelial Carcinoma of the Bladder. <i>Current Oncology Reports</i> , 2021, 23, 24.	4.0	5
9	Collaborative Review: Factors Influencing Treatment Decisions for Patients with a Localized Solid Renal Mass. <i>European Urology</i> , 2021, 80, 575-588.	1.9	48
10	Intravesical docetaxel for high-risk non-muscle invasive bladder cancer after Bacillus Calmette-Guérin failure. <i>Current Urology</i> , 2021, 15, 33-38.	0.6	2
11	National trends in clinical and pathologic staging for upper tract urothelial carcinoma: Implications for neoadjuvant chemotherapy. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2021, 39, 832.e9-832.e15.	1.6	1
12	Radical prostatectomy versus external beam radiation therapy for high-grade, clinically localized prostate cancer: Emulation of a target clinical trial. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2021, 39, 785.e1-785.e10.	1.6	4
13	Systematic review and meta-analysis of radiation therapy for high-risk non-muscle invasive bladder cancer. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2021, 39, 786.e1-786.e8.	1.6	5
14	p53 Expression, Programmed Death Ligand 1, and Risk Factors in Urinary Tract Small Cell Carcinoma. <i>Frontiers in Oncology</i> , 2021, 11, 651754.	2.8	0
15	Value-Based Healthcare in Urology: A Collaborative Review. <i>European Urology</i> , 2021, 79, 571-585.	1.9	27
16	When Less Is More: The Comparative Effectiveness of Partial Versus Radical Nephrectomy. <i>European Urology</i> , 2021, 79, 781-782.	1.9	1
17	Contemporary Incidence and Predictors of Occult Inguinal Lymph Node Metastases in Men With Clinically Node-negative (cN0) Penile Cancer. <i>Urology</i> , 2021, 153, 221-227.	1.0	7
18	Centralisation of Care for Prevalent Urological Malignancies: The Case for Prostate Cancer. <i>European Urology Focus</i> , 2021, 7, 920-923.	3.1	1

#	ARTICLE	IF	CITATIONS
19	Zonal Growth Pattern of the Prostate is Affected by Age and Body Mass Index. Journal of Urology, 2021, , 101097JU00000000000002332.	0.4	1
20	The Association of Robot-assisted Versus Pure Laparoscopic Radical Nephrectomy with Perioperative Outcomes and Hospital Costs. European Urology Focus, 2020, 6, 305-312.	3.1	20
21	Clinically node-positive (cN+) urothelial carcinoma of the bladder treated with chemotherapy and radical cystectomy: Clinical outcomes and development of a postoperative risk stratification model. Urologic Oncology: Seminars and Original Investigations, 2020, 38, 76.e19-76.e28.	1.6	8
22	Outcomes of upper tract urothelial carcinoma with isolated lymph node involvement following surgical resection: implications for multi-modal management. World Journal of Urology, 2020, 38, 1243-1252.	2.2	10
23	AUTHOR REPLY. Urology, 2020, 140, 106.	1.0	0
24	Emulating Target Clinical Trials of Radical Nephrectomy With or Without Lymph Node Dissection for Renal Cell Carcinoma. Urology, 2020, 140, 98-106.	1.0	10
25	The Role of Lymphadenectomy in Patients with Advanced Renal Cell Carcinoma. Urologic Clinics of North America, 2020, 47, 371-377.	1.8	3
26	Virtual "matchmaking" without visiting electives: Overview of the early U.S. experience and potential applications to the 2021 Canadian urology match. Canadian Urological Association Journal, 2020, 15, 141-143.	0.6	4
27	Centralization of Health Care to Facilitate Greater Use of Nephron-Sparing Surgery for Localized Renal Tumors: Identifying Appropriate Health Care Delivery. Annals of Surgical Oncology, 2020, 27, 1735-1736.	1.5	0
28	A national survey of radiation oncologists and urologists on prediction tools and nomograms for localized prostate cancer. World Journal of Urology, 2019, 37, 2099-2108.	2.2	4
29	Partial Versus Radical Nephrectomy for the Clinical T1a Renal Mass. European Urology Focus, 2019, 5, 970-972.	3.1	4
30	The natural history of renal cell carcinoma with isolated lymph node metastases following surgical resection from 2006 to 2013. Urologic Oncology: Seminars and Original Investigations, 2019, 37, 932-940.	1.6	5
31	A National Contemporary Analysis of Perioperative Outcomes for Vaginal Vault Prolapse: Minimally Invasive Sacrocolpopexy Versus Nonmesh Vaginal Surgery. Female Pelvic Medicine and Reconstructive Surgery, 2019, 25, 342-346.	1.1	13
32	The Perioperative Morbidity of Transurethral Resection of Bladder Tumor: Implications for Quality Improvement. Urology, 2019, 125, 131-137.	1.0	20
33	A National Contemporary Analysis of Perioperative Outcomes of Open versus Minimally Invasive Sacrocolpopexy. Journal of Urology, 2018, 200, 862-867.	0.4	51
34	The association of age with perioperative morbidity and mortality among men undergoing radical prostatectomy. Urologic Oncology: Seminars and Original Investigations, 2018, 36, 157.e7-157.e13.	1.6	15
35	Radical Nephrectomy with or without Lymph Node Dissection for High Risk Nonmetastatic Renal Cell Carcinoma: A Multi-Institutional Analysis. Journal of Urology, 2018, 199, 1143-1148.	0.4	46
36	The role of lymph node dissection in the management of renal cell carcinoma: a systematic review and meta-analysis. BJU International, 2018, 121, 684-698.	2.5	79

#	ARTICLE	IF	CITATIONS
37	Perioperative Morbidity of Lymph Node Dissection for Renal Cell Carcinoma: A Propensity Score-based Analysis. <i>European Urology</i> , 2018, 73, 469-475.	1.9	10
38	Perioperative Morbidity of Open Versus Minimally Invasive Partial Nephrectomy: A Contemporary Analysis of the National Surgical Quality Improvement Program. <i>Journal of Endourology</i> , 2018, 32, 116-123.	2.1	21
39	Radical Versus Partial Nephrectomy for cT1 Renal Cell Carcinoma. <i>European Urology</i> , 2018, 74, 825-832.	1.9	57
40	Risk prediction models for cancer-specific survival following cytoreductive nephrectomy in the contemporary era. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2018, 36, 499.e1-499.e7.	1.6	6
41	The association of lymph node dissection with 30-day perioperative morbidity among men undergoing minimally invasive radical prostatectomy: analysis of the National Surgical Quality Improvement Program (NSQIP). <i>Prostate Cancer and Prostatic Diseases</i> , 2018, 21, 245-251.	3.9	6
42	Using observational data for personalized medicine when clinical trial evidence is limited. <i>Fertility and Sterility</i> , 2018, 109, 946-951.	1.0	15
43	Impact of Prostate-specific Antigen (PSA) Screening Trials and Revised PSA Screening Guidelines on Rates of Prostate Biopsy and Postbiopsy Complications. <i>European Urology</i> , 2017, 71, 55-65.	1.9	43
44	Renal Cell Carcinoma with Isolated Lymph Node Involvement: Long-term Natural History and Predictors of Oncologic Outcomes Following Surgical Resection. <i>European Urology</i> , 2017, 72, 300-306.	1.9	69
45	Redefining and Contextualizing the Hospital Volume-Outcome Relationship for Robot-Assisted Radical Prostatectomy: Implications for Centralization of Care. <i>Journal of Urology</i> , 2017, 198, 92-99.	0.4	55
46	Association of Distance to Treatment Facility With Survival and Quality Outcomes After Radical Cystectomy: A Multi-Institutional Study. <i>Clinical Genitourinary Cancer</i> , 2017, 15, 689-695.e2.	1.9	14
47	The role of lymph node dissection in the contemporary management of renal cell carcinoma: A critical appraisal of the evidence. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2017, 35, 623-626.	1.6	8
48	Primum Non Nocere: Critically Assessing the Morbidity of Prostate Biopsy. <i>European Urology</i> , 2017, 71, 366-367.	1.9	2
49	Lymph Node Dissection is Not Associated with Improved Survival among Patients Undergoing Cytoreductive Nephrectomy for Metastatic Renal Cell Carcinoma: A Propensity Score Based Analysis. <i>Journal of Urology</i> , 2017, 197, 574-579.	0.4	41
50	Radical Nephrectomy With or Without Lymph Node Dissection for Nonmetastatic Renal Cell Carcinoma: A Propensity Score-based Analysis. <i>European Urology</i> , 2017, 71, 560-567.	1.9	58
51	Approach to Oligometastatic Prostate Cancer. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , 2016, 35, 119-129.	3.8	17
52	Evaluation of ≤ 0 prostate cancer in patients undergoing radical prostatectomy. <i>BJU International</i> , 2016, 118, 379-383.	2.5	7
53	Radiographic size of retroperitoneal lymph nodes predicts pathological nodal involvement for patients with renal cell carcinoma: development of a risk prediction model. <i>BJU International</i> , 2016, 118, 742-749.	2.5	32
54	Patient-reported Functional Outcomes Following Open, Laparoscopic, and Robotic Assisted Radical Prostatectomy Performed by High-volume Surgeons at High-volume Hospitals. <i>European Urology Focus</i> , 2016, 2, 172-179.	3.1	25

#	ARTICLE	IF	CITATIONS
55	Paraneoplastic syndromes are associated with adverse prognosis among patients with renal cell carcinoma undergoing nephrectomy. <i>World Journal of Urology</i> , 2016, 34, 1465-1472.	2.2	19
56	Assessing the Evidence for the Surgical Management of Renal Cell Carcinoma with Venous Tumor Thrombus: Room to Grow. <i>European Urology</i> , 2016, 70, 281-282.	1.9	6
57	Use of Personalized Printed 3-Dimensional Kidney Models for Simulation before Nephron Sparing Surgery: Methodology and Examples from a Case Series. <i>Urology Practice</i> , 2016, 3, 124-133.	0.5	2
58	The association of ABO blood type with disease recurrence and mortality among patients with urothelial carcinoma of the bladder undergoing radical cystectomy. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2016, 34, 4.e1-4.e9.	1.6	19
59	Impact of a family history of prostate cancer on clinicopathologic outcomes and survival following radical prostatectomy. <i>World Journal of Urology</i> , 2016, 34, 1115-1122.	2.2	14
60	Association of estimated glomerular filtration rate with 24-h urinalysis and stone composition. <i>Urolithiasis</i> , 2016, 44, 319-325.	2.0	7
61	A Single Dose of Intraoperative Antibiotics Is Sufficient to Prevent Urinary Tract Infection During Ureteroscopy. <i>Journal of Endourology</i> , 2016, 30, 63-68.	2.1	40
62	Comprehensive Characterization of the Perioperative Morbidity of Cytoreductive Nephrectomy. <i>European Urology</i> , 2016, 69, 84-91.	1.9	47
63	Screening for Prostate Cancer: Current Status and Future Directions. <i>European Urology Focus</i> , 2015, 1, 147-148.	3.1	1
64	Clinicopathologic characteristics and survival for adult renal sarcoma: A population-based study. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2015, 33, 505.e15-505.e20.	1.6	7
65	Comparative impact of continent and incontinent urinary diversion on long-term renal function after radical cystectomy in patients with preoperative chronic kidney disease 2 and chronic kidney disease 3a. <i>International Journal of Urology</i> , 2015, 22, 651-656.	1.0	33
66	Management of T1 Urothelial Carcinoma of the Bladder: What Do We Know and What Do We Need To Know?. <i>Bladder Cancer</i> , 2015, 2, 1-14.	0.4	6
67	Re: Comparison of MR/ultrasound fusion-guided Biopsy with Ultrasound-guided Biopsy for the Diagnosis of Prostate Cancer. <i>European Urology</i> , 2015, 68, 536-537.	1.9	1
68	Evaluation of post-operative complications and prolonged length of stay following cytoreductive nephrectomy.. <i>Journal of Clinical Oncology</i> , 2015, 33, 420-420.	1.6	0
69	Transperineal template-guided prostate biopsy for patients with persistently elevated PSA and multiple prior negative biopsies. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2013, 31, 1093-1097.	1.6	40
70	Smaller prostate gland size and older age predict Gleason score upgrading. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2013, 31, 1033-1037.	1.6	39
71	Ureteral Stenting and Retrograde Pyelography in the Office: Clinical Outcomes, Cost Effectiveness, and Time Savings. <i>Journal of Endourology</i> , 2013, 27, 662-666.	2.1	6
72	Editorial Comment. <i>Urology</i> , 2012, 79, 994-995.	1.0	0

#	ARTICLE	IF	CITATIONS
73	Relationship Between Glomerular Filtration Rate and 24-Hour Urine Composition in Patients With Nephrolithiasis. <i>Urology</i> , 2012, 80, 38-42.	1.0	21
74	Causes of renal forniceal rupture. <i>BJU International</i> , 2011, 108, 1909-1911.	2.5	81
75	High-resolution dynamics of the transcriptional response to nutrition in <i>Drosophila</i> : a key role for dFOXO. <i>Physiological Genomics</i> , 2007, 29, 24-34.	2.3	156